What it is: A synthetic heptapeptide derived from ACTH, approved in Russia as a nootropic and neuroprotective agent, studied for cognitive enhancement and stroke recovery.
Research suggests: Russian clinical trials show improvements in attention, memory, and post-stroke recovery; preclinical studies show BDNF stimulation that may explain some cognitive effects.
Best for: Cognitive enhancement and neuroprotection researchers
Key thing to know: Approved in Russia and Ukraine for clinical use; nasal spray is the standard delivery route; independent large-scale trials outside Russia have not been conducted.
What is Semax?
Semax is a synthetic heptapeptide derived from the N-terminal sequence of adrenocorticotropic hormone (ACTH), specifically the fragment ACTH(4-10), extended with a Pro-Gly-Pro sequence to increase metabolic stability and CNS penetration. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been approved in Russia and Ukraine as a nootropic and neuroprotective agent, primarily for clinical use following stroke and in the management of cognitive impairment.
Unlike ACTH itself, Semax does not stimulate cortisol secretion from the adrenal glands , it has been specifically engineered to preserve the cognitive and neuroprotective properties of the ACTH fragment without the hormonal downstream effects. This makes it distinct from typical HPA-axis peptides and positions it as a neurological research compound rather than a hormonal one.
In the nootropic community, Semax is primarily explored for cognitive enhancement, focus, and stress resilience. The formal research base, however, is concentrated in the context of neurological injury and disease , not healthy cognitive optimization , which is an important distinction when evaluating the evidence.
How Semax Works
Semax acts through the melanocortin system , it binds to melanocortin receptors (primarily MC4R) in the brain without the adrenocortical stimulation associated with full-length ACTH. MC4R activation in the CNS is associated with modulation of attention, learning, and stress response pathways. This mechanism is distinct from both dopaminergic stimulants and GABAergic anxiolytics, placing Semax in its own mechanistic category among nootropic research compounds.
Of particular significance is Semax's well-documented ability to upregulate BDNF (brain-derived neurotrophic factor) in the hippocampus and frontal cortex. BDNF is a key regulator of neuronal survival, synaptic plasticity, and long-term potentiation , the cellular basis of learning and memory. Semax-induced BDNF elevation has been observed at doses as low as 25–50 mcg in rodent models, and the effect appears to persist for several hours post-administration.
Semax also demonstrates antioxidant activity specifically within neuronal tissue, reducing reactive oxygen species in ischemic models and attenuating excitotoxic neuronal death. In stroke research, this antioxidant neuroprotection combined with BDNF upregulation represents the proposed mechanism for improved neurological recovery outcomes. Additionally, Semax influences serotonin turnover in limbic regions, which may contribute to its effects on mood and stress tolerance.
What Does the Evidence Show?
The strongest evidence for Semax comes from clinical studies in acute ischemic stroke conducted at Russian neurological research institutions. Multiple controlled trials report improved neurological recovery scores and reduced infarct-related deficits when Semax is administered intranasally in the acute and subacute stroke period. These results form the basis of its approved clinical use in Russia.
The trials are real and peer-reviewed, but all originate from within the same national research ecosystem.
Semax-induced BDNF elevation has been demonstrated consistently across multiple independent rodent studies and is one of the more reproducible findings in the Semax literature. Human BDNF data is sparse, but the mechanism is plausible and the preclinical signal is strong enough to generate significant research interest among neurologists studying cognitive rehabilitation.
The nootropic use case , improving focus, memory, or mental endurance in neurologically healthy people , is not well-supported by controlled research. Anecdotal reports are abundant and the mechanistic basis is plausible, but human RCTs in healthy subjects are absent from the published literature. Extrapolating from stroke-recovery studies to cognitive optimization in healthy individuals is a significant methodological leap.
Relevant Labs to Review
These biomarkers are most relevant to contexts in which Semax is being explored , neurological health, stress response, metabolic baseline, and inflammatory status.
Commonly Researched Alongside Semax
Semax is most often researched alongside compounds that share overlapping cognitive, neuroprotective, or anxiolytic targets. These combinations are drawn from the published and community research literature.